IP Library Granted Patent US 10,905,754
Granted Patent B2
US 10,905,754 · App. 16/417,308 · Granted Feb 2, 2021

Factor H binding proteins (fHbp) with altered properties and methods of use thereof

Inventors: Peter T. Beernink (Walnut Creek, CA); Dan M. Granoff (San Francisco, CA)
Assignee: Children's Hospital & Research Center at Oakland
A61K39/095C07K14/22A61K2039/55505A61K2039/55566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,754
App. No.
16/417,308
Granted
Feb 2, 2021
Kind
B2
Abstract

Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis , and methods of use of such proteins, are provided.

Claims (19)

1. A nucleic acid encoding a non-naturally occurring factor H binding protein (fHbp) comprising an amino acid sequence, wherein the amino acid sequence is at least 95% identical to the entire length of the amino acid sequence set forth in SEQ ID NO:1 and comprises the substitution of the arginine at position 41 with serine.

2. The nucleic acid according to claim 1 , wherein the non-naturally occurring fHbp differs from the amino acid sequence of SEQ ID NO:1 by 1 to 10 amino acids.

3. A recombinant expression vector comprising the nucleic acid of claim 1 .

4. A recombinant expression vector comprising the nucleic acid of claim 2 .

5. A genetically modified host cell comprising the nucleic acid of claim 1 .

6. A genetically modified host cell comprising the nucleic acid of claim 2 .

7. A genetically modified host cell comprising the recombinant expression vector of claim 3 .

8. A genetically modified host cell comprising the recombinant expression vector of claim 4 .

9. The genetically modified host cell of claim 5 , wherein the genetically modified host cell is a mammalian host cell.

10. The genetically modified host cell of claim 5 , wherein the genetically modified host cell is Escherichia coli ( E. coli ).

11. The genetically modified host cell of claim 5 , wherein the genetically modified host cell is a yeast cell.

12. The genetically modified host cell of claim 5 , wherein the genetically modified host cell is Neisseria meningitidis bacterium.

13. The genetically modified host cell of claim 12 , wherein the Neisseria meningitidis bacterium comprises a genetic modification that results in decreased or no detectable toxic activity of lipid A.

14. The genetically modified host cell of claim 6 , wherein the genetically modified host cell is Neisseria meningitidis bacterium.

15. The genetically modified host cell of claim 14 , wherein the Neisseria meningitidis bacterium comprises a genetic modification that results in decreased or no detectable toxic activity of lipid A.

16. The genetically modified host cell of claim 7 , wherein the genetically modified host cell is Neisseria meningitidis bacterium.

17. The genetically modified host cell of claim 16 , wherein the Neisseria meningitidis bacterium comprises a genetic modification that results in decreased or no detectable toxic activity of lipid A.

18. The genetically modified host cell of claim 8 , wherein the genetically modified host cell is Neisseria meningitidis bacterium.

19. The genetically modified host cell of claim 18 , wherein the Neisseria meningitidis bacterium comprises a genetic modification that results in decreased or no detectable toxic activity of lipid A.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: BEERNINK, PETER T.
To: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
Reel/Frame 050108/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: GRANOFF, DAN M.
To: NOVARTIS VACCINES AND DIAGNOSTICS, SRL
Reel/Frame 050108/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVARTIS VACCINES AND DIAGNOSTICS, SRL
To: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
Reel/Frame 050110/0946 →
Continuity (8)
Division 15792519 · Oct 24, 2017
Continuation 13074957 · Mar 29, 2011
Provisional Application 61440227 · Feb 7, 2011
Provisional Application 61423757 · Dec 16, 2010
Provisional Application 61381025 · Sep 8, 2010
Provisional Application 61334542 · May 13, 2010
Provisional Application 61319181 · Mar 30, 2010
Related Publication 20200000907A1 · Jan 2, 2020
Cited By (1)
US 12,269,849